Tuesday, May 28, 2024
HomeMedicineInternal MedicineCan We Diagnose a Concussion with a Blood Test?

Can We Diagnose a Concussion with a Blood Test?

The FDA reviewed a novel blood test, called the Banyan Brain Trauma Indicator, to assist in the evaluation of adults with a suspected concussion.

Mild traumatic brain injury or concussions are the results of a sudden blow to the head or a penetrating head injury that disrupts the brain’s normal functioning. Concussions often result in impaired thinking, memory, movement, sensation, or emotions. Current assessments of concussions involve the use of the 15-point Glasgow Coma Scale, which evaluates neurological function by assessing eye, verbal, and motor responses. In addition, computed tomography (CT) scans are employed to detect brain tissue damage or intracranial lesions.

The majority of patients with concussion symptoms have negative CT scans, which leads to unnecessary radiation exposure and health costs. Health care providers agree that an alternative, blood-testing option, would prevent unnecessary neuroimaging tests, radiation exposure, and health care costs. The United States Food and Drug Administration (FDA) has recently reviewed and approved marketing of a novel concussion blood test, called the Banyan Brain Trauma Indicator, for use within the next six months.

The Brain Trauma Indicator test works by measuring levels of proteins, including UCH-L1 and GFAP, which are released from the brain into the blood after a head injury. A prospective clinical study of 1,947 adults with suspected concussions demonstrated that the blood test predicted the presence of intracranial lesions on a CT scan with a 97.5% accuracy. Additionally, the indicator predicted the absence of a lesion on CT scans with a 99.6% accuracy. The findings demonstrate that the indicator can be employed as a useful tool in optimizing patient care by re-evaluating the necessity of a CT scan.

Written by Haisam Shah, BSc

Reference: FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults. U.S. Food and Drug Administration News Release. (2018). https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm596531.htm

Haisam Shah BSc
Haisam Shah BSc
Haisam is a first-year Masters student in the Department of Physiology at the University of Toronto. His research involves understanding the role of cardiac fibroblasts in the progressive development of cardiac fibrosis following a myocardial infarction. He graduated from McGill University with a Bachelors of Science – Honors in Pharmacology, where he had the opportunity of investigating potential combination therapies for Glioblastoma Multiforme.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News and Articles

SUBSCRIBE TO OUR NEWSLETTERS

Stay Connected
10,288FansLike
820FollowersFollow
249FollowersFollow
2,787FollowersFollow

Article of the month

Recognizing HIE: A Call for Advocacy

Have you heard of HIE? It’s the second leading cause of infant mortality and lifelong disability worldwide. 2-3 per 1,000 live births in high-income...

Joke Of The Day – May 28

A medical student was visiting his elderly grandfather and was asking him about the new medication that he was currently taking. "So, I understand that...

ADVERTISE WITH US

error: Content is read-only and copy-protected.